Search Results - "TEMPLETON, M. A"

Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis by Sirott, M N, Bajorin, D F, Wong, G Y, Tao, Y, Chapman, P B, Templeton, M A, Houghton, A N

“…Current methods to predict survival in patients with advanced, metastatic melanoma are limited. To determine clinical prognostic factors that accurately…”
Get more information

Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer by Jakubowski, A A, Casper, E S, Gabrilove, J L, Templeton, M A, Sherwin, S A, Oettgen, H F

“…A phase I trial of intramuscularly administered recombinant human tumor necrosis factor (rTNF) was conducted in 19 adult patients with advanced solid tumors…”
Get more information

Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites by Vadhan-Raj, S, Cordon-Cardo, C, Carswell, E, Mintzer, D, Dantis, L, Duteau, C, Templeton, M A, Oettgen, H F, Old, L J, Houghton, A N

“…Twenty-one patients were entered into a phase I trial to evaluate toxicity, antitumor effects, and biological responses at tumor sites during treatment of R24,…”
Get more information

Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma by JAKUBOWSKI, A. A, BAJORIN, D. F, GARNICK, M. B, HOUGHTON, A. N, TEMPLETON, M. A, CHAPMAN, P. B, CODY, B. V, THALER, H, YUE TAO, FILIPPA, D. A, WILLIAMS, L, SHERMAN, M. L

“…Macrophage colony-stimulating factor (M-CSF) is a lineage-specific, homodimeric growth factor that supports the proliferation and maturation of bone marrow…”
Get full text

Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma by BAJORIN, D. F, CHAPMAN, P. B, LIU, J, OETTGEN, H. F, HOUGHTON, A. N, WONG, G, COIT, D. G, KUNICKA, J, DIMAGGIO, J, CORDON-CARDO, C, URMACHER, C, DANTES, L, TEMPLETON, M. A

“…A combination of recombinant human interleukin 2 (rhIL-2) and mouse monoclonal antibody R24 (recognizing the ganglioside GD3) was evaluated in patients with…”
Get full text

Phase I Study of Escalating Doses of Edatrexate in Combination with Paclitaxel in Patients with Metastatic Breast Cancer by D'ANDREA, G, FENNELLY, D, THEODOULOU, M, TEMPLETON, M. A, YAO, T.-J, SEIDMAN, A. D, NORTON, L, BASELGA, J, GILEWSKI, T, HUDIS, C, MOYNAHAN, M. E, RAPTIS, G, SKLARIN, N, SURBONE, A

“…Motivated by the observation of preclinical synergy, a Phase I dose escalation study of edatrexate in combination with a 3-h paclitaxel infusion was performed…”
Get full text

Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma by Bajorin, D F, Chapman, P B, Wong, G Y, Cody, B V, Cordon-Cardo, C, Dantes, L, Templeton, M A, Scheinberg, D, Oettgen, H F, Houghton, A N

“…R24 is a mouse IgG3 monoclonal antibody that reacts with the ganglioside GD3 expressed by melanoma cells and other cells of neuroectodermal origin (e.g…”
Get more information

A 3-nitro triazole as a hypoxic cell sensitizer by Astor, M B, Parham, J C, Hall, E J, Templeton, M A, Hartog, B

Get full text

A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma by Steffens, T A, Bajorin, D F, Chapman, P B, Lovett, D R, Cody-Johnson, B V, Templeton, M A, Heelan, R T, Wong, G Y, Portlock, C S, Oettgen, H F

“…Cisplatin and dacarbazine are used widely in the treatment of metastatic melanoma. To evaluate high-dose cisplatin and dacarbazine, 32 patients with metastatic…”
Get more information

Synthesis of an N-aminopyrazinonium analog of cytidine by Lee, Tzoong Chyh, Chello, Paul L, Chou, Ting Chao, Templeton, Mary Agnes, Parham, James C

“…An N-aminated pyrazine analogue of cytidine, in which the pyrimidine N(3) ring nitrogen and C(4) amino group were replaced by a C-amino and an N-amino…”
Get full text

Comparative reactivities of esters of oncogenic and nononcogenic purine N-oxides and evidence of the oxidation-reduction reactivity of aromatic nitrenium ions by Parham, J C, Templeton, M A

“…Studies on the relative reactivities of esters of oncogenic and nononcogenic members of the purine N-oxide series indicate that, despite similarities in rates…”
Get full text

Teamwok manages risks more effectively by TEMPLETON, M. A, BASTA, N

Get full text

P56 Assessment and reorganization of educational training programs developed for data managers by Edelman, Bonnie, Fain, K., Templeton, MA, Houston, C.

Get full text

Manages risks more effectively by Templeton, MA

“…All plant managers in the chemical process industries (CPI) want their facilities to be safe but not CPI manager can provide an absolutely safe one. Work…”
Get full text

Competitive reactivity of nitrenium and carbenium ion contributors of purinium cations with "soft" bases by Parham, James C, Templeton, Mary Agnes

Get full text

Purine N-oxides. 65. The mechanisms of the reactions of 3-acetoxyxanthine by Templeton, Mary Agnes, Parham, James C

Get full text

Purine N-oxides. 67. Redox and rearrangement reactions of 1,7-dimethylguanine 3-oxide with anhydrides by Parham, James C, Templeton, Mary Agnes, Teller, Morris N

Get full text

Synthesis and Properties of 10-Benzylaminopterin by Parham, James C., Templeton, Mary Agnes, Chello, Paul L., Sirotnak, Francis M.

“…Substitution of a benzyl group for the methyl at N‐10 of Methotrexate caused only a slight decrease in the inhibitory properties of the folate analog against…”
Get full text